Historical note on Darwin's consideration of early-onset dementia in older persons, thirty-six years before Alzheimer's initial case report

Recent Progress in the Drug Development for the Treatment of Alzheimer's Disease Especially on Inhibition of Amyloid-peptide Aggregation

As the world 's population is aging, Alzheimer's disease (AD) has become a big concern since AD has started affecting younger people and the population of AD patients is increasing worldwide. It has been revealed that the neuropathological hallmarks of AD are typically characterized by the presence of neurotoxic extracellular amyloid plaques in the brain, which are surrounded by tangles of neuronal fibers. However, the causes of AD have not been completely understood yet. Currently, there is no drug to effectively prevent AD or to completely reserve the symptoms in the patients. This article reviews the pathological features associated with AD, the recent progress in research on the drug development to treat AD, especially on the discovery of natural product derivatives to inhibit Aβ peptide aggregation as well as the design and synthesis of Aβ peptide aggregation inhibitors to treat AD.

Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis

As the population ages due to demographic trends and gains in life expectancy, the incidence and prevalence of dementia increases, and the need to understand the etiology and pathogenesis of dementia becomes ever more urgent. Alzheimer's disease (AD), the most common form of dementia, is a complex disease, the mechanisms of which are poorly understood. The more we learn about AD, the more questions are raised about our current conceptual models of disease. In the absence of a cure or the means by which to slow disease progress, it may be prudent to apply our current knowledge of the intersection between AD, cardiovascular disease, and cerebrovascular disease to foster efforts to delay or slow the onset of AD. This review discusses our current understanding of the epidemiology, genetics, and pathophysiology of AD, the intersection between AD and vascular causes of dementia, and proposes future directions for research and prevention.

'This excellent observer ...': the correspondence between Charles Darwin and James Crichton-Browne, 1869-75

Between May 1869 and December 1875, Charles Darwin exchanged more than 40 letters with James Crichton-Browne, superintendent of the West Riding Pauper Lunatic Asylum, Wakefield, Yorkshire. This paper charts their relationship within the context of Darwin's wider research networks and methods; it analyses the contribution that Crichton-Browne made to the writing of Expression, arguing that the information he provided materially affected Darwin's thesis, and that it was partly the need to assimilate this that led Darwin to publish Expression separately from Descent. The letters help to reconstruct Crichton-Browne's early research interests, and document Darwin's little-explored role as a patron. Both men are revealed within a collaborative scientific network, with each of them at various times a beneficiary or a promoter.